Tai'ai (telitacicept) / Rongchang Pharma - LARVOL DELTA

Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review. (PubMed, Front Med (Lausanne)) - "Standard therapies, including glucocorticoids (GC), cyclophosphamide (CYC), tacrolimus (TAC), and rituximab (RTX), were ineffective. Telitacicept holds promise as a potential second-line therapy for refractory MN when conventional treatments prove ineffective. However, due to the current lack of robust evidence supporting its use in IMN, further research is warranted to establish its clinical efficacy and safety."

Journal • Monotherapy • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights. (PubMed, Am J Case Rep) - "Initial treatment with corticosteroids and cyclophosphamide showed limited efficacy. It also highlights the importance of monitoring treatment response by measuring PLA2R antibody levels. Further studies are needed to confirm the long-term efficacy of the combination of telitacicept and tacrolimus in treatment of refractory pMN."

Journal • Glomerulonephritis • Ophthalmology • Renal Disease

Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study. (PubMed, Lupus) - "The mean glucocorticoid dose (prednisone equivalent) was significantly reduced at 12 weeks (14.19 ± 8.88 mg/d, p < .001) and 24 weeks (9.86 ± 4.25 mg/d, p = .001) compared with baseline (20.87 ± 16.71 mg/d). Albumin levels also significantly improved (p = .003). Nine treatment-emergent adverse events (TEAEs) were recorded in six patients, all of which were mild and moderate.ConclusionsIn this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients."

Journal • Observational data • Real-world evidence • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Systemic Lupus Erythematosus

Efficacy and safety of telitacicept in patients with class III- V lupus nephritis: a real-world retrospective cohort study (ERA 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Efficacy Evaluation of Telitacicept in IgA Nephropathy: a real-world study (ERA 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease

Telitacicept followed by Rituximab in highly active SLE:two successful cases (ERA 2025) - No abstract available

Clinical • Inflammatory Arthritis

A comparison of the effectiveness of corticosteroids or telitacicept management alone in patients with IgA nephropathy: a retrospective observational study (ERA 2025) - No abstract available

Observational data • Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Clinical Efficacy and Safety of Telitacicept in the Treatment of Renal Involvement in Primary Sjögren's Syndrome: A Report of 4 Cases (ERA 2025) - No abstract available

Clinical • Immunology • Sjogren's Syndrome

Efficacy and Safety of Telitacicept in IgA Nephropathy: A Preliminary Report of the Large Single-center Observational Study (ERA 2025) - No abstract available

Clinical • Observational data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis Nephropathy in Children: A Retrospective Single-Center Study (ERA 2025) - No abstract available

Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease • Vasculitis

Telitacicept therapy for IgA nephropathy : A case series (ERA 2025) - No abstract available

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and safety of low-dose Telitacicept in patients with primary IgA nephropathy: a retrospective cohort study (ERA 2025) - No abstract available

Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Long-term efficacy and safety of successful pregnancy in a patient with IgA nephropathy treated with telitacicept (ERA 2025) - No abstract available

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and safety of Telitacicept treatment for proliferative sclerosis IgA nephropathy: A real-world retrospective study (ERA 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Telitacicept Therapy in Recurrent IgA Nephropathy Post-Kidney Transplantation: A Case Series and Literature Review (ERA 2025) - No abstract available

Clinical • Review • Glomerulonephritis • IgA Nephropathy • Renal Disease • Transplantation

Successful Treatment of Steroid-Dependent Mesangial Proliferative Glomerulonephritis with Telitacicept: A Case Report (ERA 2025) - No abstract available

Case report • Clinical • Glomerulonephritis • Lupus Nephritis • Nephrology

An Observational Study of Treatment on IgA Nephropathy with Telitacicept and Immunosuppressive Regimens in a Single Center (ERA 2025) - No abstract available

Clinical • Observational data • Glomerulonephritis • IgA Nephropathy • Renal Disease

Efficacy and Safety of Telitacicept in IgA Nephropathy: A Systematic Review and Meta-Analysis (ERA 2025) - No abstract available

Retrospective data • Review • Glomerulonephritis • IgA Nephropathy • Renal Disease

Long-term Telitacicept Treatment for Primary IgA nephropathy: Analysis of Five Cases (ERA 2025) - No abstract available

Clinical • Glomerulonephritis • IgA Nephropathy • Renal Disease

Real-World Study on the Effectiveness and Safety of Telitacicept in Treating IgA Nephropathy (ERA 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Renal Disease

Two Case Reports of Telitacicept Treatment in Primary IgAN with Low eGFR (ERA 2025) - No abstract available

Case report • Clinical • Glomerulonephritis • IgA Nephropathy

Long-term efficacy and safety of telitacicept in the treatment of IgAN (ERA 2025) - No abstract available

Clinical • Glomerulonephritis • IgA Nephropathy

Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series. (PubMed, J Inflamm Res) - "The average prednisone dosage was significantly reduced from 51.43±14.64 mg at baseline to 5.71±1.89 mg by week 28 (P < 0.05). IgM and IgA levels significantly declined by week 17 (P < 0.05), while BAFF levels increased significantly following telitacicept treatment by week 21 (P < 0.05). This regimen demonstrated favorable efficacy and safety, suggesting its potential as an effective option for gMG management."

Journal • Retrospective data • CNS Disorders • Infectious Disease • Myasthenia Gravis • Respiratory Diseases

Efficacy and Safety of Telitacicept as an Add-On Therapy for Refractory Immunoglobulin A Nephropathy or Immunoglobulin A Vasculitis Nephropathy in Children. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • IgA Nephropathy • Pediatrics • Renal Disease • Vasculitis

Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. (PubMed, Pediatr Nephrol) - "Telitacicept has demonstrated both efficacy and safety in treating children with refractory IgAVN."

Journal • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease • Vasculitis